Physician profile
Michael R Freeman
NPI 1851361455
$5,490.14
in general payments reported to CMS, 2019-2025
28 companies · $835 in 2025
The $835 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $619 · 2021: $885 · 2022: $636 · 2023: $1,162 · 2024: $954 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,951.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,443.22 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $725.28 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $571.09 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $371.81 | 2021-2024 | Zeposia |
| Ucb, INC. | $232.82 | 2019-2021 | |
| Pfizer INC. | $172.62 | 2022-2025 | |
| Novo Nordisk INC | $110.88 | 2021 | |
| Braintree Laboratories, INC. | $97.33 | 2021-2024 | Suflave |
| Nestle Healthcare Nutrition INC. | $93.22 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $88.85 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.51 | 2020-2025 | Xifaxan, Relistor |
| Ironwood Pharmaceuticals, INC | $68.31 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $59.92 | 2020-2021 | |
| Genzyme Corporation | $53.81 | 2022-2024 | |
| Qol Medical, LLC | $40.99 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $39.82 | 2022 | |
| Amgen INC. | $35.24 | 2020 | |
| Merck Sharp & Dohme LLC | $33.79 | 2020 | |
| Ardelyx, INC. | $33.09 | 2024-2025 | Ibsrela |
| Endo Pharmaceuticals INC. | $22.98 | 2020 | |
| Phathom Pharmaceuticals, INC. | $22.96 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $22.78 | 2025 | Rezdiffra |
| Micro-Tech Endoscopy USA, INC. | $19.63 | 2023-2024 | Abc Balloons, Sureclip |
| Astrazeneca Pharmaceuticals LP | $13.32 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.28 | 2019 | |
| Alfasigma USA, INC. | $11.79 | 2020 | |
| Redhill Biopharma INC. | $11.49 | 2021 | |
| Boston Scientific Corporation | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.